- Home
- CIGL vs ACRV Comparison
CIGL vs ACRV Comparison
Compare CIGL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- ACRV
- Stock Information
- Founded
- CIGL 1997
- ACRV 2018
- Country
- CIGL Singapore
- ACRV United States
- Employees
- CIGL N/A
- ACRV N/A
- Industry
- CIGL Diversified Commercial Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CIGL Consumer Discretionary
- ACRV Health Care
- Exchange
- CIGL Nasdaq
- ACRV Nasdaq
- Market Cap
- CIGL 46.7M
- ACRV 41.7M
- IPO Year
- CIGL 2025
- ACRV 2022
- Fundamental
- Price
- CIGL $1.96
- ACRV $1.35
- Analyst Decision
- CIGL
- ACRV Buy
- Analyst Count
- CIGL 0
- ACRV 7
- Target Price
- CIGL N/A
- ACRV $17.40
- AVG Volume (30 Days)
- CIGL 74.7K
- ACRV 253.4K
- Earning Date
- CIGL 01-01-0001
- ACRV 08-13-2025
- Dividend Yield
- CIGL N/A
- ACRV N/A
- EPS Growth
- CIGL N/A
- ACRV N/A
- EPS
- CIGL N/A
- ACRV N/A
- Revenue
- CIGL $10,490,668.00
- ACRV N/A
- Revenue This Year
- CIGL N/A
- ACRV N/A
- Revenue Next Year
- CIGL N/A
- ACRV $1,037.93
- P/E Ratio
- CIGL N/A
- ACRV N/A
- Revenue Growth
- CIGL N/A
- ACRV N/A
- 52 Week Low
- CIGL $1.70
- ACRV $1.05
- 52 Week High
- CIGL $31.06
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- ACRV 53.72
- Support Level
- CIGL N/A
- ACRV $1.20
- Resistance Level
- CIGL N/A
- ACRV $1.32
- Average True Range (ATR)
- CIGL 0.00
- ACRV 0.09
- MACD
- CIGL 0.00
- ACRV 0.00
- Stochastic Oscillator
- CIGL 0.00
- ACRV 60.00
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.